{"disease":{"id":"pulmonary-disease-chronic-obstructive","name":"pulmonary disease chronic obstructive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06053541","title":"Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change","phase":"","overall_status":"COMPLETED","enrollment_count":3015000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04926233","title":"Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study","phase":"","overall_status":"COMPLETED","enrollment_count":1371146,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02612688","title":"Pragmatic Trial of Video Education in Nursing Homes","phase":"NA","overall_status":"COMPLETED","enrollment_count":197692,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT03405363","title":"Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists","phase":"","overall_status":"COMPLETED","enrollment_count":65406,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03030638","title":"Drug Utilization Study for Olodaterol","phase":"","overall_status":"COMPLETED","enrollment_count":27606,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04184297","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":27190,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03290287","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","phase":"","overall_status":"COMPLETED","enrollment_count":26839,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06744374","title":"A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)","phase":"","overall_status":"COMPLETED","enrollment_count":22369,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03333018","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","phase":"","overall_status":"COMPLETED","enrollment_count":22155,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05393245","title":"Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data","phase":"","overall_status":"COMPLETED","enrollment_count":19467,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04097223","title":"A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)","phase":"","overall_status":"COMPLETED","enrollment_count":17464,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05402020","title":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":17018,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT01313676","title":"Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16568,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06742736","title":"EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)","phase":"","overall_status":"COMPLETED","enrollment_count":13000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05127304","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","phase":"","overall_status":"COMPLETED","enrollment_count":11316,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03979807","title":"A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)","phase":"","overall_status":"COMPLETED","enrollment_count":11296,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02164513","title":"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":10355,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03028207","title":"A Cross-sectional Study on COPD Prevalence","phase":"","overall_status":"COMPLETED","enrollment_count":9362,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04172701","title":"A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)","phase":"","overall_status":"COMPLETED","enrollment_count":9284,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05169424","title":"A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)","phase":"","overall_status":"COMPLETED","enrollment_count":9117,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03724877","title":"Effectiveness of Triple Therapy in COPD","phase":"","overall_status":"COMPLETED","enrollment_count":8853,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT00319813","title":"General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":8000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT02296138","title":"Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7903,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02719639","title":"OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)","phase":"","overall_status":"COMPLETED","enrollment_count":7443,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04249310","title":"Early Intervention Efficacy in COPD","phase":"","overall_status":"COMPLETED","enrollment_count":6788,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06573580","title":"Primary Health Management for Chronic Obstructive Pulmonary Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03299907","title":"COPD MSA 3 Regions: Epidemiology and Risk Factors of COPD in Rural Environment (BM3R)","phase":"","overall_status":"COMPLETED","enrollment_count":5263,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT03663569","title":"A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler","phase":"","overall_status":"COMPLETED","enrollment_count":4819,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05718102","title":"Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD","phase":"NA","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Seattle Institute for Biomedical and Clinical Research","has_results":false},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT03376295","title":"Comparative Effectiveness of COPD Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":3954,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03358771","title":"COPD Discharge Bundle Delivered Alone or Enhanced Through a Care Coordinator","phase":"NA","overall_status":"COMPLETED","enrollment_count":3710,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT01516528","title":"Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care","phase":"","overall_status":"COMPLETED","enrollment_count":3500,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT07103642","title":"EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)","phase":"","overall_status":"COMPLETED","enrollment_count":3402,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02864407","title":"Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease","phase":"","overall_status":"COMPLETED","enrollment_count":3223,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03467425","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":3109,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04705233","title":"Sputum Colour Charts to Guide Antibiotic Self-treatment of Acute Exacerbation of COPD (Colour COPD)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2954,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT01551758","title":"A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2802,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03034915","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2696,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04281784","title":"Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)","phase":"NA","overall_status":"COMPLETED","enrollment_count":2512,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT02668250","title":"Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality","phase":"NA","overall_status":"COMPLETED","enrollment_count":2495,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT06514144","title":"Exacerbations Among Patients Receiving Breztri (EROS Study)","phase":"","overall_status":"COMPLETED","enrollment_count":2409,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01443845","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2354,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05168722","title":"COVID-19, Patients' Evolution and the Influence of the Pandemic on Health Care and Outcomes in Chronic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2220,"lead_sponsor_name":"Hospital Galdakao-Usansolo","has_results":false},{"nct_id":"NCT00528996","title":"An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2080,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04853225","title":"Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China","phase":"","overall_status":"COMPLETED","enrollment_count":2005,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06712563","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02345161","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1811,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02675517","title":"Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":1737,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT01017952","title":"A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1635,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}